Clinical trials: Schizoaffective
Schizophrenia Spectrum Disorders, Schizophrenia
Safety and Efficacy of Virtual Reality Mindfulness in Patients With Psychosis
This study is to evaluate the safety and efficacy of Virtual Reality Mindfulness in Patients With Psychosis.
- Conditions
- Schizophrenia Spectrum Disorders, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT05784948
- Testing
- Virtual Reality Mindfulness Treatment, Experience relaxing scenery and music
- Where
- South Korea
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder
Cognitive Rehabilitation With Immersive Virtual Reality (IVR) in Schizophrenia: a Pilot Randomized Waiting List Controlled Feasibility Study
Virtual reality-based rehabilitation has recently gained increasing attention in the field of cognitive rehabilitation, allowing patients to engage in simulated real-life scenarios within a safe and controlled setting.
- Trial name
- IVR SCZ (NCT07427485)
- Testing
- CEREBRUM VR, Waiting List
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Sanitaria Locale Napoli 3 Sud, UOCSM Torre del Greco
Negative Symptoms in Schizophrenia, Schizophrenia Disorders
40 Hz Visual Stimulation as an Intervention in Schizophrenia
In schizophrenia, an abnormal reduction in neuronal gamma oscillations (30-100 Hz) is associated with negative symptoms such as cognitive dysfunction.
- Conditions
- Negative Symptoms in Schizophrenia, Schizophrenia Disorders, Schizoaffective Disorder
- Trial name
- GammaSZ (NCT06907420)
- Testing
- Visual stimulation
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Technical University of Munich
Schizophrenia, Schizoaffective Disorder
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Varenicline (Chantix) is a smoking cessation treatment that was approved in 2006 by the FDA for treatment of nicotine dependence and may be particularly beneficial in smokers with schizophrenia or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
- Trial name
- SCRP (NCT00621777)
- Testing
- Varenicline
- Where
- 10 sites in United States
- Volunteers
- 247 people
- Sponsor
- Massachusetts General Hospital
Bipolar I Disorder, Schizoaffective Disorder
Open Label Extension Study of NCT06221852
This is a 12-week open-label extension study for participants completing study NCT06221852.
- Conditions
- Bipolar I Disorder, Schizoaffective Disorder, Psychosis
- Trial name
- NCT06558201
- Testing
- Ketogenic diet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mclean Hospital
Schizophrenia, Schizoaffective Disorder
Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)
This study will test whether repetitive transcranial magnetic stimulation (rTMS) is helpful in treating negative symptoms and social deficits of schizophrenia.
- Trial name
- NCT00517075
- Testing
- Transcranial Magnetic Stimulation (TMS), repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia, Schizoaffective Disorder
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
- Trial name
- NCT00588731
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Schizophrenia Treatment Adherence Investigation (STAI)
The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia.
- Trial name
- NCT01001481
- Testing
- Risk status for medication adherence
- Volunteers
- 550 people
- Sponsor
- Janssen-Cilag Pty Ltd
Schizoaffective Disorder, Schizophrenia
Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness
Testing an mHealth mobile interventionist texting program on illness management.
- Conditions
- Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT03062267
- Testing
- Mobile Interventionist
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Washington
Schizophrenia, Bipolar Disorder
Impact of Genetic Counseling for Individuals With Mental Illness
People who have experienced mental illnesses like schizophrenia, bipolar disorder or schizoaffective disorder often have a poor understanding of the causes of their illness, and that they are often very worried about how the…
- Conditions
- Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
- Trial name
- NCT00713804
- Testing
- Genetic Counseling, Educational Booklet
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- University of British Columbia
Schizophenia Disorder, Schizoaffective Disorder
Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills
STUDY PURPOSE: To study whether patients who have schizophrenia or schizoaffective disorder and are randomly assigned to switch to aripiprazole prior to participation in a brief vocational skills training (VST) will have improved…
- Trial name
- NCT00223418
- Testing
- aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia
Antipsychotic Medication Extended Dosing Study
In patients stabilized on their antipsychotic and demonstrating evidence of good clinical response, there will not be a significant change in symptoms if their medication is decreased to every 2 days rather than daily.
- Trial name
- NCT00431574
- Testing
- dosing
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective
Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness
This is a hybrid1, effectiveness-implementation study of yoga-based exercises (YE) as an adjunctive tool for rehabilitation among persons with Severe Mental Illness (SMI).
- Conditions
- Schizophrenia, Schizoaffective, Bipolar Disorder 1
- Trial name
- ESHANTI (NCT05157620)
- Testing
- Yoga-based Exercise (YE), Wellness Lifestyle Program (WLP)
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- VA Office of Research and Development
Bipolar Disorders, Schizophrenia
Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI)
The primary aim of this study is to determine the feasibility of long-acting injectable naltrexone administration in a clinical trial in patients with SMI who also have a diagnosis of alcohol dependence.
- Conditions
- Bipolar Disorders, Schizophrenia, Schizoaffective Disorders, Alcohol Dependence
- Trial name
- vivitrol (NCT00453804)
- Testing
- injectable naltrexone, oral naltrexone
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- State University of New York - Upstate Medical University
Schizophrenia, Schizoaffective Disorder
The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia
It has been suggested that patients with schizophrenia smoke in order to produce amelioration of dysfunctional dopaminergic pathways allowing them to experience pleasure and satisfaction and overcome anhedonia.
- Trial name
- NCT00373126
- Testing
- transdermal nicotine patch
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- North Suffolk Mental Health Association
Schizophrenia
Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With Schizophrenia
The purpose of this study is to establish and validate a scale/model that can be used to evaluate the duration of time and factors between short term hospital treatment and subsequent relapse periods in patients with…
- Trial name
- PRE-COG (NCT00358852)
- Testing
- No intervention
- Volunteers
- 2,339 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Dual Diagnosis
Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
The first aim of this study is to determine whether a brain reward center (BRC) deficiency in patients with schizophrenia (SCZ) and cannabis use disorder (CUD) will be normalized when patients are given cannabis or dronabinol.
- Conditions
- Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00946348
- Testing
- Dronabinol, Cannabis
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Schizoaffective Disorder
Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia
Plasma half-life has routinely been used to establish the dosing schedule of antipsychotics; for example, it is recommended that agents with a short plasma half-life be administered multiple times per day.
- Trial name
- NCT02639702
- Testing
- Clozapine
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Cue-based Intervention in Prospective Memory and Medication Adherence.
Medication adherence is a major challenge while treating patients with major mental illnesses like schizophrenia and schizoaffective disorder.
- Trial name
- NCT06474195
- Testing
- Cue based intervention, Treatment as Usual
- Where
- India
- Volunteers
- 104 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Schizoaffective Disorder
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis
This study evaluates whether prospective pharmacogenetic testing is cost-effective in affecting clinical treatment outcomes in patients with early-phase psychosis.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT02566057
- Testing
- PGx testing guided treatment (PGT)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northwell Health